Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Welichem Biotech has completed the clinical component of a Phase IIa trial on atopic dermatitis, a form of eczema.
Subscribe to our email newsletter
The final report on this randomized, double-blinded, vehicle-controlled study to evaluate the safety, tolerability and efficacy of topically applied WBI-1001 cream in subjects with atopic dermatitis is expected later summer 2008.
The company has also initiated plans for a Phase IIb clinical trial to further evaluate the properties of WBI-1001 as a topical cream application against atopic dermatitis.